Is tamoxifen the Rosetta stone for breast cancer?

J Natl Cancer Inst. 2003 Mar 5;95(5):338-40. doi: 10.1093/jnci/95.5.338.
No abstract available

Publication types

  • Editorial
  • Review
  • Comment

MeSH terms

  • Acetyltransferases
  • Anastrozole
  • Antineoplastic Agents, Hormonal / pharmacology*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors*
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / prevention & control
  • Controlled Clinical Trials as Topic
  • Disease-Free Survival
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Histone Acetyltransferases
  • Humans
  • Metaphor
  • Nitriles / pharmacology*
  • Nitriles / therapeutic use
  • Nuclear Receptor Coactivator 1
  • Nuclear Receptor Coactivator 3
  • Oncogene Proteins
  • Phosphorylation / drug effects
  • Prospective Studies
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Selective Estrogen Receptor Modulators / pharmacology*
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Signal Transduction / drug effects
  • Tamoxifen / pharmacology*
  • Tamoxifen / therapeutic use
  • Trans-Activators / metabolism
  • Transcription Factors / metabolism
  • Treatment Failure
  • Treatment Outcome
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Biomarkers, Tumor
  • Enzyme Inhibitors
  • Nitriles
  • Oncogene Proteins
  • Receptors, Estrogen
  • Selective Estrogen Receptor Modulators
  • Trans-Activators
  • Transcription Factors
  • Triazoles
  • Tamoxifen
  • Anastrozole
  • Acetyltransferases
  • Histone Acetyltransferases
  • NCOA1 protein, human
  • NCOA3 protein, human
  • Nuclear Receptor Coactivator 1
  • Nuclear Receptor Coactivator 3
  • Receptor, ErbB-2